Deutsche Bank AG Grows Stake in Dyne Therapeutics, Inc. $DYN

Deutsche Bank AG grew its position in shares of Dyne Therapeutics, Inc. (NASDAQ:DYN) by 347.7% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 317,664 shares of the company’s stock after purchasing an additional 246,703 shares during the period. Deutsche Bank AG owned approximately 0.28% of Dyne Therapeutics worth $3,323,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. GF Fund Management CO. LTD. purchased a new position in Dyne Therapeutics in the fourth quarter worth $50,000. Arizona State Retirement System grew its position in Dyne Therapeutics by 9.2% in the first quarter. Arizona State Retirement System now owns 17,501 shares of the company’s stock worth $183,000 after acquiring an additional 1,481 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank grew its position in Dyne Therapeutics by 22.2% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 19,247 shares of the company’s stock worth $201,000 after acquiring an additional 3,496 shares in the last quarter. Summit Investment Advisors Inc. grew its position in Dyne Therapeutics by 9.1% in the fourth quarter. Summit Investment Advisors Inc. now owns 8,627 shares of the company’s stock worth $203,000 after acquiring an additional 721 shares in the last quarter. Finally, Neo Ivy Capital Management bought a new stake in Dyne Therapeutics in the fourth quarter worth $205,000. 96.68% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Dyne Therapeutics

In other Dyne Therapeutics news, CEO John Cox bought 100,000 shares of the firm’s stock in a transaction on Monday, July 14th. The stock was acquired at an average price of $9.11 per share, with a total value of $911,000.00. Following the completion of the purchase, the chief executive officer owned 242,179 shares of the company’s stock, valued at approximately $2,206,250.69. This trade represents a 70.33% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 20.77% of the stock is currently owned by insiders.

Dyne Therapeutics Stock Down 0.4%

Shares of NASDAQ:DYN opened at $12.33 on Tuesday. Dyne Therapeutics, Inc. has a 1 year low of $6.36 and a 1 year high of $47.45. The company has a market cap of $1.75 billion, a PE ratio of -3.19 and a beta of 1.08. The stock’s 50-day moving average is $10.42 and its 200 day moving average is $11.25. The company has a debt-to-equity ratio of 0.17, a current ratio of 16.83 and a quick ratio of 16.83.

Dyne Therapeutics (NASDAQ:DYN) last released its quarterly earnings results on Monday, July 28th. The company reported ($0.97) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.99) by $0.02. Sell-side analysts anticipate that Dyne Therapeutics, Inc. will post -3.44 EPS for the current year.

Analysts Set New Price Targets

Several analysts have weighed in on the stock. Jones Trading assumed coverage on shares of Dyne Therapeutics in a research note on Thursday, June 26th. They issued a “buy” rating and a $30.00 price target for the company. Oppenheimer lowered their price target on shares of Dyne Therapeutics from $34.00 to $13.00 and set an “outperform” rating for the company in a research note on Wednesday, August 6th. Robert W. Baird lowered their price target on shares of Dyne Therapeutics from $46.00 to $32.00 and set an “outperform” rating for the company in a research note on Wednesday, June 18th. Stifel Nicolaus lowered their price target on shares of Dyne Therapeutics from $66.00 to $36.00 and set a “buy” rating for the company in a research note on Thursday, July 31st. Finally, Chardan Capital lowered their price target on shares of Dyne Therapeutics from $50.00 to $38.00 and set a “buy” rating for the company in a research note on Tuesday, July 29th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, twelve have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $33.80.

Dyne Therapeutics Company Profile

Dyne Therapeutics, Inc, a clinical-stage muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It is developing a portfolio of muscle disease therapeutics, including programs in myotonic dystrophy type 1; duchenne muscular dystrophy; and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics.